DemeRx announced in late April 2026 that the FDA has accepted its Investigational New Drug (IND) application for DMX-1001, an oral noribogaine formulation being developed as a treatment for alcohol use disorder. This is the first time the FDA has allowed a clinical study of an ibogaine-derived compound in the United States.
What Noribogaine Is
Ibogaine is a naturally occurring psychoactive alkaloid from the African plant Tabernanthe iboga. Noribogaine is ibogaine primary metabolite. Unlike ibogaine, which clears the body in 4-7 hours, noribogaine remains active for 24-48+ hours or longer, driving neuroplastic changes that may help repair circuits damaged by chronic substance use. DemeRx designed DMX-1001 specifically to reduce the cardiac risks associated with the parent compound.
Where the Research Stands
DemeRx recently completed a multiple ascending dose trial in healthy volunteers with acceptable safety and tolerability. The FDA IND acceptance green-lights Phase 2 trials in people with alcohol use disorder. Alcohol use disorder affects more than 29 million Americans and is a leading cause of preventable death. Fewer than 10% of people with AUD receive medication-assisted treatment.
Why This Matters for People in Recovery
The FDA willingness to clear ibogaine-derivative research in the U.S. reflects a broader shift in how regulators are approaching psychedelic-adjacent compounds with addiction medicine potential. Find current alcohol use disorder treatment options near you.
Sources Cited
- 01.BDemeRx Announces FDA Acceptance of IND Application for DMX-1001BioSpace / DemeRx Press Release
- 02.A
Filed Under
sciencetreatmentIbogaineFDAClinical Trial
Keep up with the reporting.
One email each morning with the stories that put days like this in context.